Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 37
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Kirschner, Matthias Aleman, André and Kaiser, Stefan 2016. Secondary negative symptoms — A review of mechanisms, assessment and treatment. Schizophrenia Research,

    Chee, Kok-Yoon Tripathi, Adarsh Avasthi, Ajit Chong, Mian-Yoon Sim, Kang Yang, Shu-Yu Glover, Sandeep Xiang, Yu-Tao Si, Tian-Mei Kanba, Shigenobu He, Yan-Ling Lee, Min-Soo Chiu, Helen Fung-Kum Kuga, Hironori Mahendran, Rathi Udormatn, Pichet Kallivayalil, Roy A Tanra, Andi J Maramis, Margarita Shinfuku, Naotaka Shen, Winston W Tan, Chay-Hoon and Sartorius, Norman 2015. International study on antidepressant prescription pattern at 40 major psychiatric institutions and hospitals in Asia: A 10-year comparison study. Asia-Pacific Psychiatry, Vol. 7, Issue. 4, p. 366.

    Hasan, Alkomiet Falkai, Peter Wobrock, Thomas Lieberman, Jeffrey Glenthøj, Birte Gattaz, Wagner F. Thibaut, Florence and Möller, Hans-Jürgen 2015. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry, Vol. 16, Issue. 3, p. 142.

    Jung, Woo-Young Kim, Sung-Gon Lee, Jin-Seong Kang, Dong-Ho Jung, Bong-Joo Shin, Dong-Hun Lee, Young-Min and Choi, Sang-Heon 2015. Open prospective study of ziprasidone in patients with schizophrenia with depressive symptoms: A multicenter study. Psychiatry and Clinical Neurosciences, Vol. 69, Issue. 1, p. 43.

    Sharma, Ajaykumar N. Ligade, Sagar S. Sharma, Jay N. Shukla, Praveen Elased, Khalid M. and Lucot, James B. 2015. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metabolic Brain Disease, Vol. 30, Issue. 2, p. 519.

    Vernon, Jeffrey A. Grudnikoff, Eugene Seidman, Andrew J. Frazier, Thomas W. Vemulapalli, Mani Sandhya Pareek, Priyanki Goldberg, Terry E. Kane, John M. and Correll, Christoph U. 2014. Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis. Schizophrenia Research, Vol. 159, Issue. 2-3, p. 385.

    Hinkelmann, Kim Yassouridis, Alexander Kellner, Michael Jahn, Holger Wiedemann, Klaus and Raedler, Thomas J. 2013. No Effects of Antidepressants on Negative Symptoms in Schizophrenia. Journal of Clinical Psychopharmacology, Vol. 33, Issue. 5, p. 686.

    King, Robert and Kavanagh, David J. 2013. Manual of Psychosocial Rehabilitation.

    Xiang, Yu-Tao Ungvari, Gabor S. Wang, Chuan-Yue Si, Tian-Mei Lee, Edwin H.M. Chiu, Helen F.K. Lai, Kelly Y.C. He, Yan-Ling Yang, Shu-Yu Chong, Mian-Yoon Tan, Chay-Hoon Kua, Ee-Heok Fujii, Senta Sim, Kang Yong, Michael K.H. Trivedi, Jitendra K. Chung, Eun-Kee Udomratn, Pichet Chee, Kok-Yoon Sartorius, Norman and Shinfuku, Naotaka 2013. Adjunctive antidepressant prescriptions for hospitalized patients with schizophrenia in Asia (2001-2009). Asia-Pacific Psychiatry, Vol. 5, Issue. 2, p. E81.

    Lindström, Eva Eriksson, Lars and Levander, Sten 2012. Suicides during 7 years among a catchment area cohort of patients with psychoses. Nordic Journal of Psychiatry, Vol. 66, Issue. 1, p. 8.

    Rybakowski, Janusz K. Vansteelandt, Kristof Szafranski, Tomasz Thys, Eric Jarema, Marek Wolfgang Fleischhacker, W. Kahn, René S. and Peuskens, Joseph 2012. Treatment of depression in first episode of schizophrenia: Results from EUFEST. European Neuropsychopharmacology, Vol. 22, Issue. 12, p. 875.

    Babinkostova, Zoja and Stefanovski, Branislav 2011. Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression. EPMA Journal, Vol. 2, Issue. 4, p. 391.

    Buckley, Peter F Pillai, Anilkumar and Howell, Kristy R 2011. Brain-derived neurotrophic factor: findings in schizophrenia. Current Opinion in Psychiatry, Vol. 24, Issue. 2, p. 122.

    Leucht, Stephan Correll, Christoph U. and Kane, John M. 2011. Schizophrenia.

    Leucht, Stefan Heres, Stephan Kissling, Werner and Davis, John M. 2011. Evidence-based pharmacotherapy of schizophrenia. The International Journal of Neuropsychopharmacology, Vol. 14, Issue. 02, p. 269.

    Power, Paddy 2011. Promoting Recovery in Early Psychosis.

    Englisch, Susanne Inta, Dragos Eer, Andrea and Zink, Mathias 2010. Bupropion for Depression in Schizophrenia. Clinical Neuropharmacology, Vol. 33, Issue. 5, p. 257.

    Nielsen, J. Le Quach, P. Emborg, C. Foldager, L. and Correll, C. U. 2010. 10-Year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatrica Scandinavica, Vol. 122, Issue. 5, p. 356.

    Tandon, Rajiv Nasrallah, Henry A. and Keshavan, Matcheri S. 2010. Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future. Schizophrenia Research, Vol. 122, Issue. 1-3, p. 1.

    Zink, Mathias Englisch, Susanne and Meyer-Lindenberg, Andreas 2010. Polypharmacy in schizophrenia. Current Opinion in Psychiatry, Vol. 23, Issue. 2, p. 103.


Antidepressants for the treatment of depression in people with schizophrenia: a systematic review

  • C. WHITEHEAD (a1), S. MOSS (a1), A. CARDNO (a1) and G. LEWIS (a1)
  • DOI:
  • Published online: 01 May 2003

Background. Depression is common in people with schizophrenia and is associated with substantial morbidity and an increased risk of suicide. Our aim was to review systematically all the randomized controlled trials that have investigated the clinical effectiveness of antidepressant medication in the treatment of depression in people who also suffer with schizophrenia.

Method. Electronic searches of ClinPsych, the Cochrane Library, the Cochrane Schizophrenia Group's Register of Trials, EMBASE and Medline were completed. Reference lists from identified articles were hand searched.

Results. Eleven small studies were identified and all randomized fewer than 30 subjects to each group. We could only perform analyses on a subset of the trials. For five trials (aggregate N=209) the proportion improved in the antidepressant group was 26% (95% CI 10% to 42%) higher than in the placebo group. In six studies (aggregate N=267) the standardized mean difference on the Hamilton Rating Scale for Depression at the end of the trial was −0·27 (95% CI −0·7 to 0·2). There was no evidence that antidepressant treatment given during the stable phase of illness led to a deterioration of psychotic symptoms in the included trials.

Conclusions. The literature reviewed was, overall, of poor quality and only a small number of trials could contribute towards the meta-analysis. The results provide weak evidence for the effectiveness of antidepressants in those with schizophrenia and depression and could be explained by publication bias. We need further research to determine the best approach towards treating depression in people with schizophrenia.

Corresponding author
Professor Glyn Lewis, University of Bristol, Cotham House, Cotham Hill, Bristol BS6 6JL.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *